Compare Summit Therapeutics Inc (SMMT) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Weibo Corp — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: Summit Therapeutics Inc is far larger — about 5.4× Weibo Corp's market cap, and Weibo Corp pays a 7.63% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WB | |
|---|---|---|
Market Cap | $10.48B | $1.95B |
Sector | Health | Media |
52-Week High | $29.32 | $12.83 |
52-Week Low | $13.05 | $7.20 |
Enterprise Value | $9.90B | $1.22B |
Dividend Yield | — | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Weibo (WB) trades at $8.00, up 3.23% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.15% net income margin and trades at discounted valuations including a P/E of 5.59 and P/B of 0.51. Recent earnings missed expectations for three consecutive quarters, but the company maintains robust cash flow generation and a solid balance sheet with $2.35 billion in cash.
The outlook is mixed: deep value metrics and analyst buy ratings (45%) support upside potential, but competitive pressures and recent earnings misses pose risks. The stock's 8% dividend yield provides income support while investors await improved execution and AI monetization opportunities to drive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
